Two consecutive phase II trials of biweekly oxaliplatin plus weekly 48-hour continuous infusion of nonmodulated high-dose 5-fluorouracil as first-line treatment for advanced colorectal cancer

Clinical Colorectal Cancer

Volumn 4, Issue 6, 2005, Pages 384-389

  Abad, Albert ^a   Carrato, Alfredo ^b   Navarro, Matilde ^c   Sastre, Javier ^d   Cervantes, Andrés ^e   Antón, Antonio ^f   Martinez Villacampa, Mercedes ^c   Marcuelllo, Eugenio ^g   Massutí, Bartomeo ^h   Aranda, Enrique ⁱ   Manzano, José Luis ^a   Guallar, José Luis ^j   Diaz Rubio, Eduardo ^d  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^c HOSPITAL DURAN I REYNALS   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^f HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^g HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^h HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

ⁱ HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^j Sanofi Synthelabo   (Spain)

more..

Author keywords

Diarrhea; Heamatologic toxicity; Neurologic toxicity; Paresthesia

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER PATIENT; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INCIDENCE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PAIN; PARESTHESIA; PHASE 2 CLINICAL TRIAL; SENSORY DYSFUNCTION; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; COLORECTAL TUMOR; DISEASE COURSE; DOSE RESPONSE; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; SURVIVAL ANALYSIS;

EID: 21344456723     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2005.n.010     Document Type: Article

References (27)

1. Heidelberger C, Chaudhari NK, Danneberg P. Fluorinated pyrimidine. A new class of tumor-inhibitory compounds. Nature 1957; 179:663-666.
2. Advanced colorectal meta-analysis project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer. Evidence in terms of response rate. J Clin Oncol 1992; 10:896-903.
3. de Gramont A, Basset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer. A French Intergroup Study. J Clin Oncol 1997; 15:808-815.
4. Aranda E, Diaz-Rubio E, Cervantes A, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: A Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) Study. Ann Oncol 1998; 9:727-731.
5. Diaz-Rubio E, Aranda E, Martin M, et al. Weekly high-dose infusion of 5-fluorouracil in advanced colorectal cancer. Eur J Cancer 1990; 26:727-729.
6. Aranda E, Cervantes A, Dorta J, et al. A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer. The Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD). Cancer 1995; 76:559-563.
7. Aranda E, Cervantes A, Carrato A, et al. Outpatient weekly high-dose continuous infusion 5-fluorouracil plus oral leucovorin in advanced colorectal cancer. A phase II trial. Ann Oncol 1996; 7:581-585.
8. Cvitkovic E, Bekradda M. Oxaliplatin: a new therapeutic option in colorectal cancer. Semin Oncol 1999; 26:647-662.
9. Schmoll HJ, Cassidy J. Integrating oxaliplatin into the management of colorectal cancer. Oncologist 2001; 6(suppl 4):24-28.
10. Pelley RJ. Oxaliplatin: a new agent for colorectal cancer. Curr Oncol Rep 2001; 3:147-155.
11. Machover D, Diaz-Rubio E, de Gramont A, et al. Two consecutive phase II trials of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996; 7:95-98.
12. Bertheault-Cvitkovic F, Jami A, Ithzaki M, et al. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 1996; 14:2950-2958.
13. de Gramont A, Vignoud J, Tournigand C, et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48 hrs continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997; 33:214-219.
14. Maindrault-Goebel F, Louvet C, Andre T, et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer 1999; 35:1338-1342.
15. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-2947.
16. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18:136-147.
17. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47:207-214.
18. Guidelines for the reporting of adverse drug reactions. Bethesda, MD: Division of Cancer Treatment, National Cancer Institute; 1988.
19. Moehler M, Hoffmann T, Hildner K, et al. Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with irinotecan and folinic acid/5-fluorouracil regimens. Z Gastroenterol 2002; 40:957-964.
20. Giacchetti S, Itzhaki M, Gruia G, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10:663-669.
21. Sorbye H, Dahl O. Nordic 5-fluorouracil/leucovorin bolus schedule combined with oxaliplatin (Nordic FLOX) as first-line treatment of metastatic colorectal cancer. Acta Oncol 2003; 42:827-831.
22. Maindrault-Goebel F, de Gramont A, Louvet C, et al. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group. Ann Oncol 2000; 11:1477-1483.
23. Haller DG. Safety of oxaliplatin in the treatment of colorectal cancer. Oncol (Huntingt) 2000; 14(12 suppl 11): 15-20.
24. Kohne CH, Cunningham D, Di CF, et al. Clinical determinants of survival in patients with 5-fluorouracil based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002; 13:308-317.
25. Fountzilas G, Gossios K, Zisiadis A, et al. Prognostic variables in patients with advanced colorectal cancer treated with fluorouracil and leucovorin-based chemotherapy. Med Pediatr Oncol 1996; 26:305-317.
26. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905-914.
27. Steinberg J, Erlichman C, Gadalla T, et al. Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid. Eur J Cancer 1992; 28A:1817-182.